Nektar Therapeutics

Prosight Management disclosed a purchase of 180,367 Nektar Therapeutics shares, an estimated $10.27 million addition that raised its reported stake to $52.88 million and 8.7% of reportable AUM. The move comes as Nektar prepares to start the Phase 3 ZENITH-AD program for rezpegaldesleukin and schedules an End-of-Phase 2 meeting with the FDA for alopecia areata. Nektar has strengthened its cash position to over $1 billion including recent offering proceeds, but its valuation remains dependent on late-stage trial success. » More on finance.yahoo.com

Nektar Therapeutics presented positive data from two phase‑2b studies of rezpegaldesleukin at the American Academy of Dermatology congress: the REZOLVE‑AD study showed significant improvements in the Eczema Area and Severity Index (EASI) across all severities, and the REZOLVE‑AA study achieved a statistically significant reduction in SALT scores for alopecia areata after population adjustment. The company plans to start the phase‑3 ZENITH‑AD program for moderate to severe atopic dermatitis in Q2 2026. Despite a roughly 520% share price increase over the past year, Nektar remains unprofitable with a loss of $9.73 per share; analysts nevertheless have price targets between $70 and $165 and some consider the stock overvalued. Rezpegaldesleukin has FDA Fast Track designation for both indications. » More on de.investing.com

Nektar Therapeutics stock hit a 52-week high of $77.36 and is currently trading at $77.46, representing a one-year increase of about 481% and a market capitalization of roughly $2.2 billion. Investor confidence is attributed to the promising pharmaceutical pipeline, while InvestingPro classifies the stock as significantly overvalued. Nektar reported cash reserves of $245.8 million at the end of Q4 2025 and available capital of around $720 million after financing actions; the company continues to focus on R&D. Oppenheimer raised its price target to $140 (Outperform), TD Cowen started coverage with Buy (target $109) and Wedbush with Neutral; data on rezpegaldesleukin from two Phase 2b studies are expected to be presented at AAD 2026. » More on de.investing.com